Axogen, Inc. reported second quarter 2026 financial results with revenue of $69.7 million, representing a 23.1% increase from the prior year period. The company raised its full-year 2026 revenue guidance to at least $279 million, reflecting expected growth of at least 24%. Axogen reported a GAAP net loss of $1.5 million, or $0.03 per share, compared to net income of $0.6 million in the same quarter last year. Adjusted net income was $7.3 million, or $0.12 per share, while adjusted EBITDA came in at $8.4 million. The company holds $113.4 million in cash and investments as of June 30, 2026, having extinguished its long-term debt during the first half of the year. Axogen operates in the medical device industry, developing and marketing innovative surgical solutions for peripheral nerve regeneration and repair.
